PTCH1 expression at diagnosis predicts imatinib failure in chronic myeloid leukaemia patients in chronic phase

American Journal of Hematology

Volumn 90, Issue 1, 2015, Pages 20-26

  Alonso Dominguez, Juan M ^a   Grinfeld, Jacob ^a,b   Alikian, Mary ^a   Marin, David ^a,b   Reid, Alistair ^a,b   Daghistani, Mustafa ^a   Hedgley, Corinne ^c   O'Brien, Stephen ^c   Clark, Richard E ^d   Apperley, Jane ^a,b   Foroni, Letizia ^a,b   Gerrard, Gareth ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BENZAMIDE DERIVATIVE; CELL SURFACE RECEPTOR; IMATINIB; PATCHED RECEPTORS; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; TRANSCRIPTOME;

COHORT ANALYSIS; DISEASE FREE SURVIVAL; DRUG RESISTANCE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETICS; HUMAN; KAPLAN MEIER METHOD; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, CHRONIC-PHASE; MIDDLE AGED; MORTALITY; PILOT STUDY; PREDICTIVE VALUE; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TREATMENT FAILURE;

BENZAMIDES; COHORT STUDIES; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; IMATINIB MESYLATE; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, CHRONIC-PHASE; MIDDLE AGED; PILOT PROJECTS; PIPERAZINES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECEPTORS, CELL SURFACE; SENSITIVITY AND SPECIFICITY; TRANSCRIPTOME; TREATMENT FAILURE;

EID: 84919607950     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23857     Document Type: Article

References (34)

1. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
2. De Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: Incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008;26:3358-3363.
3. De Lavallade H, Finetti P, Carbuccia N, et al. A gene expression signature of primary resistance to imatinib in chronic myeloid leukemia. Leuk Res 2010;34:254-257.
4. Yong ASM, Szydlo RM, Goldman JM, et al. Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML. Blood 2006;107:205-212.
5. Oehler VG, Yeung KY, Choi YE, et al. The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data. Blood 2009;114:3292-3298.
6. McWeeney SK, Pemberton LC, Loriaux MM, et al. A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib. Blood 2010;115:315-325.
7. Villuendas R, Steegmann JL, Pollán M, et al. Identification of genes involved in imatinib resistance in CML: A gene-expression profiling approach. Leukemia 2006;20:1047-1054.
8. Zhang WW, Cortes JE, Yao H, et al. Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. J Clin Oncol 2009;27:3642-3649.
9. Zheng C, Li L, Haak M, et al. Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis. Leukemia 2006;20:1028-1034.
10. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-2417.
11. Hasford J, Baccarani M, Hoffmann V, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: The EUTOS score. Blood 2011;118:686-692.
12. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013;122:872-884.
13. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: An update of concepts and management recommendations of European Leukemia Net. J Clin Oncol 2009;27:6041-6051.
14. O'Brien SG, Deininger MWN. Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia. Semin Hematol 2003;40:26-30.
15. Foroni L, Gerrard G, Nna E, et al. Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemia. Am J Hematol 2009;84:517-522.
16. Foroni L, Wilson G, Gerrard G, et al. Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia. Br J Haematol 2011;153:179-190.
17. Beillard E, Pallisgaard N, van der Velden VHJ, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using "real-time" quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)-A Europe against cancer program. Leukemia 2003;17:2474-2486.
18. Ito T, Kwon HY, Zimdahl B, et al. Regulation of myeloid leukaemia by the cell-fate determinant Musashi. Nature 2010;466:765-768.
19. Ochi T, Fujiwara H, Suemori K, et al. Aurora-A kinase: A novel target of cellular immunotherapy for leukemia. Blood 2009;113:66-74.
20. Uehara E, Takeuchi S, Yang Y, et al. Aberrant methylation in promoter-associated CpG islands of multiple genes in chronic myelogenous leukemia blast crisis. Oncol Lett 2012;3:190-192.
21. Otahalova E, Ullmannova-Benson V, Klamova H, et al. WT1 expression in peripheral leukocytes of patients with chronic myeloid leukemia serves for the prediction of Imatinib resistance. Neoplasma 2009;56:393-397.
22. Daghistani M, Khorashad J, Milojkovic D, et al. Enhanced expression of the Hedgehog pathway target gene PTCH1 predicts inferior response to Imatinib [abstract]. Haematologica 2011;Abstract 522.
23. Radich JP, Dai H, Mao M, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA 2006;103:2794-2799.
24. Mohty M, Yong ASM, Szydlo RM, et al. The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia. Blood 2007;110:380-383.
25. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods 2001;25:402-408.
26. Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002;3:RESEARCH0034.
27. Bustin SA, Benes V, Garson JA, et al. The MIQE guidelines: Minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009;55:611-622.
28. Swerdlow S, Campo E, Harris NL, et al, editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: International Agency for Research on Cancer (IARC); 2008. 439 p.
29. Holcik M, Korneluk RG. Functional characterization of the X-linked inhibitor of apoptosis (XIAP) internal ribosome entry site element: Role of La autoantigen in XIAP translation. Mol Cell Biol 2000;20:4648-4657.
30. Suzuki M, Hatsuse H, Nagao K, et al. Selective haploinsufficiency of longer isoforms of PTCH1 protein can cause nevoid basal cell carcinoma syndrome. J Hum Genet 2012;57:422-426.
31. Villavicencio EH, Walterhouse DO, Iannaccone PM. The sonic hedgehog-patched-gli pathway in human development and disease. Am J Hum Genet 2000;67:1047-1054.
32. Liao H-F, Su Y-C, Zheng Z-Y, et al. Sonic hedgehog signaling regulates Bcr-Abl expression in human chronic myeloid leukemia cells. Biomed Pharmacother 2012;66:378-383.
33. Zhao C, Chen A, Jamieson CH, et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 2009;458:776-779.
34. Cea M, Cagnetta A, Cirmena G, et al. Tracking molecular relapse of chronic myeloid leukemia by measuring Hedgehog signaling status. Leuk Lymph 2013;54:342-352.